Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
Abstract Background Gilteritinib is the only drug approved as monotherapy for acute myeloid leukemia (AML) patients harboring FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation throughout the world. However, drug resistance inevitably develops in clinical. Sitravatinib is a m...
Main Authors: | Yvyin Zhang, Peihong Wang, Yang Wang, Yang Shen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-01-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40364-022-00447-4 |
Similar Items
-
Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
by: Katagiri S, et al.
Published: (2023-07-01) -
Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
by: R. Iannotta, et al.
Published: (2022-01-01) -
Detection of FLT3 Oncogene Mutations in Acute Myeloid Leukemia Using Conformation Sensitive Gel Electrophoresis
by: Mamdooh Gari, et al.
Published: (2008-11-01) -
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
by: Tecik M, et al.
Published: (2022-11-01) -
FLT3 - ITD positive acute lymphocytic leukemia, does it impact on disease´s course?
by: Sebastian Kobold, et al.
Published: (2010-06-01)